INTRODUCTION

Cancer is one of the fatal disease and leading cause of death in the world (Ferlay et al., 2013). Accounting to statistical analysis of American Cancer Society at National Cancer Institute of the USA, 580350 worldwide deaths in 2013 was due to cancer (Atlanta, 2013). 14.1 million new cases of cancer per year in the world was estimated by GLOBOCAN 2012 which expected to be increased by 19.3 million new cases of cancer per year by 2025 (Ferlay et al., 2013). There are mainly four methods to treat cancer including Surgery, chemotherapy radiation, and immunotherapy (Masood, 2016). However, poor prognosis, poor bioavailability, lack of selectivity, inconsistency in the systemic circulation, non-specific biodistribution and severe side effects are major limitations of conventional cancer therapy (Cho et al., 2008; Soni and Yadav, 2015). Chemotherapy has a number of advantages, however it is associated with a variety of challenges due to lack of selectivity and associated high toxicity. The main reasons for the failure of chemotherapy includes poor solubility of drug, narrow therapeutic index and efflux of drug from cells by several efflux transporters leading to hampered pharmacokinetic profile (Bansal et al., 2009; Parhi et al., 2012; Saneja et al., 2014). Therefore, a harmless, efficient and novel treatment strategy, especially for chemotherapeutic agents are immediately needed to fight against cancer.